Overview

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Status:
Recruiting
Trial end date:
2028-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Genentech, Inc.
Treatments:
Lenalidomide
Obinutuzumab